ALISO VIEJO, CA--(Marketwire - May 16, 2011) - CNS Response, Inc.
) announced today that it is launching the Psychiatric EEG Evaluation Registry
, or PEER Online
™, a cloud-based platform which allows physicians to exchange outcome data referenced to their patients' neurophysiology.
The PEER Online service will allow physicians to compare and learn which medication treatments have been effective, and which have not been effective for their peers treating patients with similar brain patterns. It builds on the company's original physician-developed database, Referenced-EEG® (rEEG®).
"Finding the right medication for an individual patient suffering from mental health issues is one of the biggest challenges facing medical professionals," said Daniel Hoffman, M.D., chief medical officer of CNS Response. "Most mental health medications are currently prescribed through trial and error, a process that can be detrimental to patients and their families. Medications affect everyone differently, and with over 130 psychotropic medications to choose from, it is difficult for physicians to know which regimen is best. Using PEER Online, medical professionals will have the ability to exchange clinical data on which medications were successful and which medications failed compared to an individual patient's neurophysiology."
"This is based on a transformative idea which dramatically changed outcomes in childhood cancers," said CNS Response CEO George Carpenter.
In the 1970s, oncologists treating pediatric cancer developed a registry that helped them network and compare treatment regimens and patient outcomes, in order to advance knowledge of pediatric cancer. The system, which is still in place, enables physicians to learn what works and what does not for treating pediatric cancer, and has significantly improved children's cancer survival and recovery rates.
"As a cloud-based outcome registry, PEER Online will provide the same kind of vital exchange of information between medical professionals treating patients with mental health issues," said Carpenter.
Medical professionals interested in learning more can contact CNS Response at PEERinfo@cnsresponse.com.
While most physicians are able to base their treatment decisions on objective data gathered from EKGs, MRIs, blood tests and similar procedures, such advances have not previously been available to medical professionals treating mental illness.
Mental health treatment based on trial and error has often lead to unneeded suffering, unwanted side effects from ineffective medications, and increased costs to patients, families, employers and health care payers. In fact, so-called treatment resistant patients have almost double the number of medical office visits, nearly three times the outpatient claims, and nearly four times the inpatient claims as patients who are effectively treated, adding an estimated $8,500 in extra costs per patient per year.
About CNS Response
CNS Response provides reference data and analytic tools for clinicians and researchers through PEER Online, a new registry and reporting platform. The registry builds on the company's original physician-developed database called Referenced-EEG® (rEEG®). Developed with clinical data supplied by physicians, PEER Online serves as a platform for medical professionals to exchange treatment outcome data referenced to objective neurophysiology data from EEG. Physicians using this information have consistently reported reduction in their use of trial and error pharmacotherapy. To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.